Aimmune Therapeutics (NASDAQ:AIMT) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($1.03) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.03), Briefing.com reports. During the same period last year, the company earned ($0.89) earnings per share.
Shares of NASDAQ AIMT traded up $1.11 during trading on Friday, hitting $29.48. 626,600 shares of the company traded hands, compared to its average volume of 717,952. Aimmune Therapeutics has a 1 year low of $16.95 and a 1 year high of $31.83. The company has a quick ratio of 5.80, a current ratio of 5.80 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $1.82 billion, a P/E ratio of -8.03 and a beta of -0.03. The company has a 50-day moving average price of $24.90 and a 200-day moving average price of $21.36.
Several research analysts have weighed in on the company. Royal Bank of Canada cut their price target on Aimmune Therapeutics to $50.00 and set an “outperform” rating for the company in a report on Friday, August 9th. ValuEngine upgraded Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, November 4th. Stifel Nicolaus upgraded Aimmune Therapeutics to a “positive” rating in a report on Monday, September 16th. Wedbush reiterated a “buy” rating on shares of Aimmune Therapeutics in a report on Thursday, October 31st. Finally, Goldman Sachs Group set a $27.00 price target on Aimmune Therapeutics and gave the company a “hold” rating in a report on Friday, October 25th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $43.11.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.